Your Due Diligence Found the Risks. Did It Identify What Must Be Fixed First?
SAI WHITE PAPER SERIES
Your Due Diligence Found the Risks. Did It Identify What Must Be Fixed First?
How PE Deal Teams Can Distinguish Diligence Findings From the Condition Most Likely to Govern Post-Close Performance
Lawrence M. Schneider
Founder & CEO, Schneider Axiom Institute™
PUBLICATION IDENTITY
Permanent Publication Identifier: SAI-ACPP-10
Original Publication: June 2026
Current Editorial Revision: September 2026
Version: 2.0
Classification: Private Equity & Transaction Analysis
Subject: Due Diligence, Investment Thesis & Post-Close Operating Priority
Primary Audience: Private Equity Deal Teams, Operating Partners, Investment Committee Members & Value-Creation Teams
SAI Discipline Stage: IDENTIFY → PRIORITIZE
Evidence Orientation: Interpretive Proposition Supported by Private-Equity Due-Diligence, Governance, Value-Creation, and Post-Buyout Performance Research, Operating Observation, and Illustrative Scenarios
Executive Abstract
A private-equity deal team can complete a rigorous due-diligence process and still enter the first 100 days with one question unresolved:
Which condition should the portfolio company address first?
Quality of earnings may test reported EBITDA. Commercial diligence may test market size, customer behavior, competition, and pricing. Operational diligence may examine capacity, process, technology, procurement, and execution. Management assessment may evaluate leadership capability and depth. Legal, tax, IT, cybersecurity, environmental, and regulatory diligence may identify additional risks.
All of that work matters.
But the 100-day plan still requires a different decision:
Which finding is most likely to limit the performance required by the investment thesis?
Not every diligence issue deserves first priority. Not every material risk is currently governing performance. And not every weakness should become a workstream simply because it appeared in a diligence report.
Due diligence identifies what the deal team needs to know before close. Diagnostic priority determines what the company should address first after close.
THE CENTRAL PROPOSITION
Private-equity due diligence can identify financial, operational, management, legal, market, technology, and transaction risks without necessarily determining which condition will most limit post-close performance. Before the 100-day plan converts diligence findings into workstreams, the deal team can distinguish material risks, competing explanations, and the condition that deserves first operating priority. The purpose is not to replace standard diligence, but to improve the sequence from diligence finding to post-close action.
The issue is not whether the diligence was thorough. It is what happens after the findings arrive.
A deal team may know that customer concentration is high, gross margin has declined, the CEO remains central to major decisions, systems require investment, sales productivity varies by region, working capital is weak, integration capability is limited, and management depth is thin. All can be true.
The next question is:
Which one must be addressed first if the investment thesis is to work?
Why This Paper Matters
Due diligence produces information before capital is committed. The 100-day plan converts that information into action after close.
A diligence report may contain twenty important findings. Management cannot make twenty things the first priority. The Operating Partner cannot allocate equal attention to every issue. The portfolio company cannot restructure pricing, sales, operations, systems, leadership, customer concentration, working capital, and organization simultaneously without creating its own execution problem.
The team therefore needs more than a list of risks. It needs a sequence.
The question is not simply, "What did diligence find?" It is:
"Which finding is most likely to prevent the company from producing the result assumed in the investment thesis?"
Due Diligence and Diagnosis Answer Different Questions
Due diligence asks whether the deal team understands the business well enough to make an informed investment decision. Diagnosis asks which condition deserves operating priority. Those questions overlap. They are not identical.
A quality-of-earnings review may establish that EBITDA adjustments are aggressive. That matters. But it does not automatically identify what is limiting operating performance.
A commercial review may confirm an attractive market. That supports the thesis. But the company may still be unable to convert demand because of positioning, sales execution, capacity, or credibility.
A management assessment may conclude that the team is capable. That does not establish whether the organization gives that team the authority or resources required to execute.
An operational review may identify several inefficiencies. That does not establish which one is governing EBITDA.
A diligence finding can be material without being the first condition management should fix.
Thorough Due Diligence Matters
This paper does not argue that diligence is incomplete by design. Research supports its importance.
Cumming and Zambelli found that more thorough private-equity due diligence was associated with improved investee performance, with fund-manager-led diligence showing particularly strong relationships in their sample. [1]
The correct conclusion is therefore not:
"Due diligence misses the real problem."
It is:
"Due diligence can produce many useful findings, and those findings still have to be prioritized for post-close action."
That is the diagnostic step examined here.
The Investment Thesis Contains Assumptions About Cause and Effect
Every investment thesis contains operating assumptions. Revenue will grow. Margin will improve. Pricing will strengthen. The sales force will become more productive. Procurement will improve. Management will scale. Working capital will improve. Capacity will support growth.
These are not merely forecasts. They imply:
If we change these conditions, these financial results should follow.
The deal team therefore needs to know whether the selected condition is actually limiting the required result.
A spreadsheet can calculate the expected improvement precisely. It cannot prove that the selected initiative will cause it.
Illustrative Scenario: Customer Concentration
A target company has one customer representing 34 percent of revenue. Commercial diligence identifies the concentration. The finding is material.
Should reducing concentration become the first post-close priority? Maybe. But further questions matter.
Is the relationship stable? Are margins attractive? Does the customer exert unusual pricing power? Is concentration increasing? Can the company add customers without adding capacity? Is another condition preventing growth?
The concentration may be the governing problem. Or it may be a serious risk that should be managed while another condition receives first operating priority.
The existence of a material risk does not automatically establish sequencing.
Illustrative Scenario: The Management Team Looks Strong
Management diligence concludes that the CEO and leadership team are capable. References are strong. Historical execution is credible. The deal closes.
Post-close, major decisions continue to bottleneck through the founder, who remains involved in selected customer and operating matters.
The management assessment was not necessarily wrong. The team may be fully capable. The problem may be the decision structure in which the team is operating. Replacing managers would address the wrong issue.
The more useful question is:
Does the team lack capability—or does the organization prevent capable managers from exercising it?
Illustrative Scenario: The Margin Opportunity
Operational diligence identifies procurement savings and labor-efficiency opportunities. The 100-day plan builds workstreams around both. After close, costs improve. Margin remains below thesis.
Further examination shows that the business shifted toward customers and products with lower contribution margins. The procurement findings were real. The efficiency findings were real. The initiatives produced savings. But they were not sufficient to restore the economics assumed in the thesis.
A diligence finding can be correct, actionable, and still not be the condition governing the required result.
Illustrative Scenario: The Add-On Strategy
A platform thesis depends on add-on acquisitions. Diligence confirms an attractive pipeline. The first add-on closes. Integration stalls. The issue is initially labeled execution.
But several causes remain possible: systems do not integrate; local leaders retain authority; the platform lacks integration staff; the acquired company uses a different operating model; customer workflows do not transfer; or the platform itself was not ready to absorb more volume.
Calling the issue "integration execution" does not determine the response.
Before the next add-on accelerates, the team should know what prevented the first one from integrating as planned.
A 100-Day Plan Can Become a List of Diligence Findings
Commercial diligence identifies pricing opportunity. Operational diligence identifies labor efficiency. IT diligence identifies systems gaps. Management assessment identifies leadership-development needs. Finance identifies working-capital improvement. Procurement identifies vendor savings.
The post-close plan now contains six workstreams. That can look disciplined. But one question remains:
Which workstream should receive first management attention because it is most likely to govern the performance required by the thesis?
A complete workstream list is not the same as a priority sequence.
What Private-Equity Research Adds
The PE literature supports the importance of both investment selection and post-close value creation.
Gompers, Kaplan, and Mukharlyamov found that PE investors report relying heavily on operational improvement and growth initiatives as sources of value creation, alongside governance and financial decisions. [2]
Acharya and colleagues found associations between stronger deal performance, active sponsor involvement, operating-margin improvement, productivity initiatives, organic growth, and support for management. [3]
Krysta and Kanbach found substantial variation in value-creation mechanisms, investor roles, context, and outcomes across the literature. [4]
Broader reviews likewise emphasize that private-equity outcomes vary by firm, transaction, sponsor, and operating environment. [5][6]
That supports a practical point:
There is no single post-close lever that works because the company is PE-backed. The intervention must fit the condition actually limiting that company.
The Diligence Finding and the Operating Priority Should Be Separated
A diligence finding answers:
What did we discover?
An operating priority answers:
What should management address first?
Suppose diligence finds: 25 percent customer concentration; a weak CRM; $1 million of procurement opportunity; high founder dependence; slow inventory turns; and an attractive geographic expansion opportunity. Each may justify action.
But if founder dependence prevents the management team from making pricing, hiring, and customer-allocation decisions without approval, that condition may need to be addressed before several other initiatives can work. Alternatively, founder dependence may be manageable and working capital may be the real limit. The evidence must decide.
Priority should follow the business condition—not the order in which findings appear in the diligence report.
The Seven Classes Organize Competing Explanations
The Seven Classes of Business Constraint™ are:
Market · Operational · Financial · Organizational · Strategic · Leadership · Credibility
They widen the inquiry before the team narrows the priority.
A revenue issue may originate in Market demand, Strategic positioning, Operational capacity, Leadership decisions, or Credibility with buyers. A margin issue may originate in Operations, Strategy, pricing, organization, or market pressure. A working-capital issue may be Financial—or the downstream result of inventory, fulfillment, collections, growth, or operating policy. A management issue may be Leadership—or an Organizational problem involving authority and accountability.
The classes do not determine the answer.
They prevent the team from assuming that the location of the symptom is necessarily the location of the cause.
Risk and Governing Constraint Are Different
Due diligence identifies risk. Diagnosis asks a different question.
A risk asks:
What could harm this investment?
A governing constraint asks:
What condition is limiting the required performance now?
Customer concentration may be a significant risk without limiting current EBITDA. Cybersecurity may require immediate remediation without governing revenue growth. Management succession may matter greatly to exit while another condition is governing performance today. Both categories matter.
Not every material risk is the governing constraint, and the governing constraint does not explain every material risk.
Sometimes the Investment Thesis Is the Problem
A structured diagnosis should not force every problem into a correctable internal explanation. Sometimes the market is smaller than expected. Competition is stronger. Regulation changes. A customer leaves. Input costs shift. Or the purchase price embedded assumptions that operating improvements cannot reasonably support.
Sometimes the correct finding is:
The investment thesis itself needs to change.
Diagnosis should improve judgment, not protect the original thesis from being questioned.
When Should the Deal Team Ask the Diagnostic Question?
The most useful point is when diligence findings are being translated into the investment thesis and post-close priorities. That is where the deal team can ask:
What results must improve? What conditions are assumed to produce that improvement? What evidence supports those assumptions? What other explanations could produce the same historical symptoms? Which condition appears to deserve priority? What would tell us we are wrong?
Those questions can fit inside existing diligence and IC preparation.
The goal is not another report. It is a better connection between what diligence found and what management does after close.
The Business Constraint Diagnostic™ as One Structured Input
The Business Constraint Diagnostic™ is SAI's structured instrument for examining the probable governing constraint class and the condition indicated by the information supplied.
It costs $89, contains 81 questions, typically requires about 30 minutes, and produces a 2,200+ word written finding within 72 hours.
The finding addresses the probable governing constraint class, the condition indicated by the evidence supplied, why that condition appears limiting, why prior efforts failed, and the corrective direction suggested by the diagnosis.
For a PE deal team, the Diagnostic can provide an additional structured view before post-close priorities are finalized.
It does not replace quality of earnings, commercial diligence, operational diligence, management assessment, legal diligence, tax diligence, IT or cybersecurity diligence, valuation, investment-committee judgment, or the 100-day planning process.
Nor should it be treated as independent proof of causation.
The Diagnostic identifies a probable governing constraint. The deal team must test that finding against the evidence already produced through diligence.
Guarantee: "If your written finding does not identify a clear, actionable governing constraint, your $89 will be refunded."
A Better Pre-Close Conversation
Instead of:
"Commercial diligence found customer concentration, so diversification goes into the 100-day plan."
ask:
"Is concentration limiting current performance, threatening future performance, or simply a material risk we need to manage?"
Instead of:
"Operational diligence found labor inefficiency, so productivity becomes a workstream."
ask:
"What evidence tells us labor efficiency is limiting margin rather than mix, pricing, capacity, or another cause?"
Instead of:
"Management assessment identified a weak functional leader, so we need a replacement."
ask:
"Is performance weak because the leader lacks capability, because authority is unclear, because resources are insufficient, or because the plan itself is unrealistic?"
These questions do not reject diligence findings. They determine how those findings should be used.
Questions That Strengthen the Investment Thesis
Before the 100-day plan is finalized, the deal team should be able to ask:
What performance improvement does the investment thesis require? What does diligence say is preventing that improvement today? What competing explanations remain plausible? Which condition appears to be limiting the required result now? What must change first? What result should improve if the diagnosis is correct? What evidence would tell us the diagnosis was wrong? What material risks remain important even though they are not the first operating priority?
That sequence does not guarantee a successful deal. It makes the operating logic of the thesis clearer.
IDENTIFY → PRIORITIZE → RESOLVE → CONFIRM
The Business Constraint Discipline™ uses the sequence:
IDENTIFY → PRIORITIZE → RESOLVE → CONFIRM
Applied to pre-close and post-close work: IDENTIFY asks what condition best fits the diligence evidence. PRIORITIZE asks whether that condition deserves first operating attention. RESOLVE applies the appropriate corrective action after close. CONFIRM determines whether the condition and required performance actually changed.
If the expected result does not improve, the team must revisit the original assumption.
A strong investment thesis should contain a way to discover when one of its operating assumptions failed.
What This Paper Does Not Claim
This paper does not claim that standard private-equity due diligence is inadequate. It does not claim that quality of earnings is merely backward-looking or that operational diligence examines only symptoms. It does not claim that sophisticated deal teams fail to identify structural causes. It does not claim that every acquisition has a governing constraint that can be identified before close. It does not claim that the Business Constraint Diagnostic™ completes due diligence.
It does not claim that using the Diagnostic changes purchase price, prevents underperformance, increases EBITDA, improves IRR or MOIC, shortens holding periods, improves exit multiples, or produces better transaction outcomes. It does not claim that SAI's framework is superior to diagnostic approaches already used by PE firms, consultants, operating partners, or diligence providers. And it does not claim that the external scholarship cited here independently validates the Business Constraint Discipline™, the Seven Classes of Business Constraint™, the governing-constraint proposition, or the Business Constraint Diagnostic™.
The proposition is narrower:
Before diligence findings become post-close workstreams, explicitly determining which condition deserves first operating priority can strengthen the connection between pre-close analysis and post-close action.
Implications / Applications
Preserve the strength of existing diligence. Use its evidence rather than compete with it. Separate material risk from first operating priority. Test the causal assumption behind each value-creation workstream. Keep the investment thesis open to revision. Limit the number of first priorities. Confirm whether the condition actually changed.
A completed workstream is not proof that the governing condition changed.
Limitations and Questions for Further Examination
The scenarios in this paper are illustrative. They are not presented as verified SAI acquisition case histories.
Private-equity diligence varies considerably by fund, transaction size, strategy, sector, geography, advisor mix, and deal complexity. Some firms already use operating and causal frameworks that may accomplish part or all of what this paper describes.
The cited research supports the importance of thorough diligence, active ownership, investment selection, and post-close operating improvement. It does not establish the effectiveness of SAI's diagnostic framework.
Further examination should test whether explicitly prioritizing diligence findings before the 100-day plan changes management focus, workstream selection, operating improvement, or the frequency with which original initiatives must be redesigned.
The central empirical question is:
Does adding a formal priority diagnosis between due diligence and the 100-day plan improve post-close operating decisions compared with an otherwise strong PE process that does not use one?
That should be tested. Not assumed.
Conclusion
Due diligence can tell the deal team a great deal about a business. It can test earnings. Challenge market assumptions. Assess management. Inspect operations. Identify legal exposure. Evaluate systems. Expose customer concentration. Test working capital. Stress the model. That work matters.
But before every important finding becomes a post-close workstream, one more question deserves an answer:
What must this business address first if the investment thesis is to work?
The answer may already be obvious from diligence. Good. Make it explicit.
The answer may require additional investigation. Do that before management is asked to execute six priorities simultaneously.
The answer may even be that the investment thesis itself needs revision. That is also valuable.
Due diligence tells you what you found. Diagnosis tells you what deserves priority.
Use the evidence. Compare the explanations. Choose the first target carefully. Measure what changes. Then decide what comes next.
Diagnosis before prescription.
Evidence Boundary
This paper advances an SAI interpretive proposition concerning the distinction between due-diligence findings and post-close operating priority in private-equity transactions.
The proposition is informed by research on private-equity due diligence, investment selection, active ownership, governance, value creation, and post-buyout operating performance, together with operating observation and illustrative scenarios.
The paper does not establish that standard due diligence fails to identify governing conditions, that formal diagnostic approaches outperform existing PE methods, or that use of the Business Constraint Diagnostic™ improves transaction or portfolio-company outcomes.
The Seven Classes of Business Constraint™ remain Market, Operational, Financial, Organizational, Strategic, Leadership, and Credibility.
The scenarios are illustrative and are not presented as verified SAI transaction histories.
External scholarship supports the intellectual context surrounding due diligence, active ownership, investment selection, operating improvement, and heterogeneous post-buyout outcomes. It does not independently validate the Business Constraint Discipline™, the Seven Classes of Business Constraint™, the governing-constraint proposition, SAI credentials, or the Business Constraint Diagnostic™.
The Business Constraint Diagnostic™ is a business diagnostic instrument. It is not quality of earnings, commercial diligence, operational diligence, management assessment, financial diligence, legal diligence, tax diligence, valuation, investment advice, or an investment-committee recommendation.
References
[1] Cumming, D., & Zambelli, S. (2017). Due Diligence and Investee Performance. European Financial Management, 23, 211–253. https://doi.org/10.1111/eufm.12100
[2] Gompers, P. A., Kaplan, S. N., & Mukharlyamov, V. (2016). What Do Private Equity Firms Say They Do? Journal of Financial Economics, 121, 449–476. https://doi.org/10.1016/j.jfineco.2016.06.003
[3] Acharya, V. V., Gottschalg, O. F., Hahn, M., & Kehoe, C. (2010). Corporate Governance and Value Creation: Evidence from Private Equity. https://doi.org/10.2139/ssrn.1324016
[4] Krysta, P. M., & Kanbach, D. K. (2022). Value creation in private equity portfolio companies: a structured review of evidence and proposed framework. Venture Capital, 24, 203–286. https://doi.org/10.1080/13691066.2022.2117669
[5] McGrath, P. J., & Nerkar, A. (2022). Private Equity: Antecedents, Outcomes, Mediators, and Moderators. Journal of Management, 49, 158–195. https://doi.org/10.1177/01492063221127907
[6] Davis, S. J., Haltiwanger, J. C., Handley, K., Lipsius, B., Lerner, J., & Miranda, J. (2025). The (Heterogeneous) Economic Effects of Private Equity Buyouts. Management Science, 71, 9569–9587. https://doi.org/10.1287/mnsc.2021.03890
Related SAI Resources
Business Constraint Diagnostic™ →
What Is a Business Constraint? →
The Seven Classes of Business Constraint™
How the Seven Classes of Business Constraint™ Work Together
Why Diagnostic Credentials Matter →
CAS — Certified Axiom Strategist →
CAE — Certified Axiom Executive →
About the Author
Lawrence M. Schneider is the Founder and CEO of the Schneider Axiom Institute and the founder of U.S. Lock Corporation, now owned by The Home Depot. He brings more than five decades of CEO-level operating experience across manufacturing, distribution, land development, residential and commercial construction, franchising, and multi-entity businesses. He developed the Business Constraint Discipline™ to help owners, executives, and advisors identify what is limiting a business, determine what deserves priority, and confirm whether corrective action worked.
About the Schneider Axiom Institute
The Schneider Axiom Institute is an Institute for Business Constraints. Its work is organized around a disciplined premise: diagnosis should precede prescription. Through research, practitioner education, diagnostic instruments, and credentials, SAI develops the capability to identify, prioritize, resolve, and confirm the governing constraint.